Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Progesterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.95 |
| ▸ | LMNA | P02545 | 7/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.95 |
| ▸ | MAPT | P10636 | 5/20 | 0.95 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.95 |
| ▸ | TSHR | P16473 | 4/20 | 0.95 |
| ▸ | SHBG | P04278 | 4/20 | 0.95 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.95 |
| ▸ | AR | P10275 | 3/20 | 0.95 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.95 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.95 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Progesterone SCHEMBL28901829 | 0.99 | CYP3A4 (0.93) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL10791303 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20409003 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL13259536 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL7671 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL23568915 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL15224316 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20342397 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL8430168 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL3932110 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118858479-A | Kit for simultaneously detecting 90 steroid hormones and metabolites thereof in urine sample, detection method and sample pretreatment method | 中国疾病预防控制中心环境与健康相关产品安全所 | 2024-10-29 | — | — | CN | claimed |
| CN-117030904-B | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-12-19 | — | — | CN | claimed |
| CN-117030904-A | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-11-10 | — | — | CN | claimed |
| CN-107011333-B | Bifunctional molecules with antibody recruiting and human immunodeficiency virus entry inhibiting activity | 耶鲁大学 | 2021-03-19 | — | — | CN | claimed |
| CN-108623648-A | Nomegestrol acetate crystal form I and its preparation method and application | 国家卫生计生委科学技术研究所 | 2018-10-09 | — | — | CN | claimed |
| EP-3376977-A1 | RECOVERY AND PROCESSING OF HUMAN EMBRYOS FORMEDIN VIVO | Previvo Genetics, Inc. (US) | 2018-09-26 | — | — | EP | claimed |
| CN-108467420-A | A kind of Nomegestrol acetate crystal form II and preparation method thereof | 国家卫生计生委科学技术研究所 | 2018-08-31 | — | — | CN | claimed |
| CN-105924487-B | The preparation process of 17a- hydroxyl progesterone acetates | 湖北丹澳药业有限公司 | 2018-07-24 | — | — | CN | claimed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | claimed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | claimed |
| US-20020010167-A1 | Starter kit for low dose oral contraceptives | AMERICAN HOME PRODUCTS CORPORATION | 2002-01-24 | — | — | US | claimed |
| WO-2001093848-A2 | STARTER KIT FOR LOW DOSE ORAL CONTRACEPTIVES | WYETH (US) | 2001-12-13 | — | — | WO | claimed |
| EP-0954260-A1 | COMPOSITIONS, METHODS AND DEVICES FOR THE TRANSDERMAL DELIVERY OF DRUGS | Diversified Pharmaceuticals, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| US-5891462-A | GEL MIXTURE CONTAINING PERMEABILITY ENHANCER | PERMATEC N.V. (NL) | 1999-04-06 | — | — | US | claimed |
| US-5788983-A | LEVONORGESTREL, 17-BETA ESTRADIOL, NORETHINDIONE, ETHYL ESTRADIOL, MEDROXY PROGESTERONE ACETATE, TESTOSTERONE | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-08-04 | — | — | US | claimed |
| WO-1997043989-A1 | COMPOSITIONS, METHODS AND DEVICES FOR THE TRANSDERMAL DELIVERY OF DRUGS | DIVERSIFIED PHARMACEUTICALS, INC. (US) | 1997-11-27 | — | — | WO | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| US-5164190-A | Hydrophobic drugs, steroids | THERATECH, INC. (US) | 1992-11-17 | — | — | US | claimed |
| CN-1041528-A | HORMONE PREPARATION AND METHOD | JENCAP RESEARCH LTD (CA) | 1990-04-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | PGR 1415/4885CYP3A4 385/4885LMNA 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.